Related Experiment Video
Updated: Sep 10, 2025

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
Published on: November 9, 2017
A Possible Association Between Rituximab and the Subsequent Development of Guillain-Barré Syndrome: A Case Report
Lilian Chen1, Stephen Lee Yu2, Nolan Holley1
1Department of Internal Medicine, West Virginia University, Morgantown, WV 26506, USA.
Diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab may develop Guillain-Barré syndrome (GBS). Early recognition of this rituximab-induced GBS is crucial for prompt treatment and improved patient outcomes.
Area of Science:
- Neurology
- Oncology
- Immunology
Background:
- Hematologic malignancies, such as diffuse large B-cell lymphoma (DLBCL), are linked to Guillain-Barré syndrome (GBS).
- Rituximab, an immunomodulator, is a key component in DLBCL treatment and its use is increasing.
- The potential for rituximab to induce GBS necessitates clinical awareness.
More Related Videos
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
09:54Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020